Instruction for use: Finasteride

Active substance:

Finasteride

ATX code

G04CB01 Finasteride

Pharmacological group

Androgens, antiandrogens

Means that affect the metabolism in the prostate gland, and correctors urodynamics

Nosological classification (ICD-10)

N40 Prostatic hyperplasia

Prostate adenoma, BPH, Hypertrophy of the prostate, Hypertrophy of the prostate, Dysuric disorders due to benign prostatic hyperplasia, Dysuria with prostatic adenoma, Benign prostatic hyperplasia, Benign prostatic hyperplasia of stage 1 and 2, Benign prostatic hyperplasia of the first degree, Benign prostatic hyperplasia of II degree, Benign prostatic hypertrophy, Disease of the prostate, Acute urinary retention associated with benign prostatic hyperplasia, Benign prostatic hyperplasia 1 and 2 stages in combination with prostatitis, The paradoxical ishuria

Composition

1 tablet, coated with a shell, contains finasteride 5 mg; In a contour acheikova packing 10 pcs., In a cardboard bundle 1 packing.

pharmachologic effect

Pharmacological action - antiandrogenic.

Inhibits 5-alpha-reductase and lowers the biosynthesis of dihydrotestosterone.

Pharmacodynamics

With constant admission, the effect manifests itself after 3 months (decrease in the volume of the prostate gland), 4 months (an increase in the maximum rate of urine flow), and 7 months (decrease in general symptoms and signs of urinary tract obstruction).

Pharmacokinetics

It is well absorbed and penetrates into tissues and biofluids, incl. In the ejaculate.

Indications

Prostate adenoma.

Contraindications

Hypersensitivity.

Side effects

On the part of the genitourinary system: impotence, weakening of the libido, decrease in the volume of the ejaculate.

Dosing and Administration

Inside, 5 mg / day for 6 months or more.

Precautionary measures

During treatment in patients with a large volume of residual urine and / or a significant decrease in its passage, it is necessary to monitor the possible development of obstructive uropathy. Ineffective in patients with malignant degeneration of the prostate. Do not assign to women and children.

storage Conditions

In a dry place protected from light.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiry date printed on the package.